Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Adipotide
Weight Management
AOD-9604
Weight Management
BPC-157
Healing & Recovery
Cagrilintide
Weight Management
CJC-1295
Growth Hormone
DSIP
Sleep & Recovery
Epithalon
Anti-Aging
GHK-Cu
Anti-Aging
GHRP-2
Growth Hormone
HCG
Hormone Support
Hexarelin
Growth Hormone
HGH
Growth Hormone
IGF-1 LR3
Growth Hormone
Kisspeptin
Hormone Support
Melanotan-2
Cosmetic
MOTS-C
Metabolic
NAD+
Anti-Aging
Oxytocin Acetate
Hormone Support
PEG-MGF
Recovery
PT-141
Sexual Health
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Snap-8
Cosmetic
SS-31
Mitochondrial
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Thymosin Alpha-1
Immune
Tirzepatide
Weight Management
Total Peptides: 31
Back to Home
Kisspeptin
EfficacyHigh
Studies8
Participants187
StatusAvailable

Kisspeptin

Kisspeptin-54 / Kisspeptin-10

Kisspeptin is a neuropeptide encoded by the KISS1 gene that plays a critical role in regulating the hypothalamic-pituitary-gonadal (HPG) axis. It stimulates gonadotropin-releasing hormone (GnRH) secretion by binding to the GPR54/Kiss1R receptor, making it essential for reproductive function, puberty onset, and fertility. Originally discovered as a metastasis suppressor in certain cancers, kisspeptin has emerged as a promising therapeutic target for reproductive disorders including infertility, hypothalamic amenorrhea, and hypoactive sexual desire disorder.

Complete Research Database

KISSPEPTIN-IVF Trial

View Study

Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization

JournalJournal of Clinical Investigation (2014)
Participants53
DurationSingle dose study

PRIMARY RESULTS

23% clinical pregnancy rate with kisspeptin-54 vs conventional hCG triggering, with significantly reduced OHSS risk

KEY FINDINGS

  • 85-95% oocyte maturation rates depending on dose
  • Mean mature oocyte count 11.2 ± 4.7 per patient
  • LH surge comparable to natural mid-cycle peaks (43.2 ± 15.8 IU/L)
  • Zero cases of ovarian hyperstimulation syndrome

HYPOACTIVE Trial

View Study

Effects of Kisspeptin Administration in Women With Hypoactive Sexual Desire Disorder

JournalJAMA Network Open (2022)
Participants32
Duration75-minute infusion

PRIMARY RESULTS

Kisspeptin modulated sexual and attraction brain processing with no adverse effects during fMRI assessment

KEY FINDINGS

  • Enhanced brain activity in sexual processing regions
  • Improved response to attraction stimuli
  • No treatment-related adverse events
  • Potential therapeutic target for HSDD

PCOS Ovulation Study

View Study

Kisspeptin treatment induces gonadotropic responses and rescues ovulation in women with PCOS

JournalJournal of Clinical Endocrinology & Metabolism (2019)
Participants24
Duration21 days

PRIMARY RESULTS

Significant rise in LH and estradiol levels with ovulation achieved in subset of participants

KEY FINDINGS

  • Restored gonadotropin responsiveness
  • Induced follicular growth in anovulatory women
  • Variable individual responses based on PCOS phenotype
  • Promising alternative to traditional ovulation induction

Medical Disclaimer

Kisspeptin is in Phase 2 clinical trials for reproductive applications. This information is for educational purposes only and should not be construed as medical advice. Any clinical use should occur only under medical supervision in approved research or clinical settings.